This post was originally published on this site.
Dr. Martens has reaffirmed its guidance for FY27 after reporting that trading since the start of the financial year has been in line with expectations.
Ahead of its Annual General Meeting on Wednesday, the footwear brand said it remains on track to deliver the strategic priorities outlined alongside its full-year results in May, with no changes to its outlook.
The company said it continues to focus on its ambition of becoming the “world’s most-desired premium footwear brand”, with priorities for the year including increasing full-price sales in the UK and DACH markets, launching a new sandals range, rolling out new retail concepts in key cities and unlocking further benefits from its operating model and technology investments.
Dr. Martens added that its largest market, the US, continues to grow, with wholesale performance proving particularly encouraging. Japan and South Korea are also performing well, while European markets are trading as expected despite a challenging consumer backdrop.
The update follows the group’s return to profit growth in FY26, when pre-tax profit increased as the business continued its shift to a consumer-first operating model. At the time, Dr. Martens said FY27 would mark the beginning of the “scale” phase of its longer-term growth strategy, with plans to increase brand investment and upgrade selected retail stores.
Earlier this year, the business also restructured its senior leadership team, introducing dedicated General Managers across key markets as part of efforts to simplify its operating model and strengthen local consumer engagement.